Vitamin Supplements Show No Clear Benefit for Cancer Patients, Review Finds
A critical review of preclinical and clinical studies finds little evidence that vitamin supplements improve cancer outcomes, calling for tighter regulation.
Summary
This 2025 review in Expert Review of Anticancer Therapy examined whether vitamins and dietary supplements benefit cancer patients. Analyzing studies from PubMed and ClinicalTrials.gov, the authors found that despite vitamins playing essential roles in immune function, antioxidant defense, and epigenetic regulation, clinical trials have not demonstrated meaningful benefits of over-the-counter supplements on cancer prognosis or health outcomes. Cancer patients frequently develop vitamin deficiencies due to inflammation, cachexia, and treatment side effects, yet supplementation alone appears insufficient. Dietary strategies like intermittent fasting and ketogenic diets were also reviewed with mixed conclusions. The authors call for a dedicated regulatory authority to oversee nutraceutical product quality before commercialization, warning that unregulated supplements may be useless or potentially harmful.
Detailed Summary
Vitamins are fundamental micronutrients that support immune function, antioxidant defense, epigenetic regulation, and microbiota balance. Given their biological importance, there has been longstanding interest in whether supplementing these nutrients could help prevent or treat cancer, particularly as cancer patients are disproportionately affected by vitamin deficiencies driven by chronic inflammation, tumor metabolism, and the side effects of anticancer therapies.
This comprehensive review, published in Expert Review of Anticancer Therapy, critically examined preclinical and clinical studies sourced from PubMed and ClinicalTrials.gov to assess the potential benefits of vitamin supplementation and dietary interventions — including intermittent fasting and ketogenic diets — in both mouse tumor models and human cancer patients.
Despite promising signals in animal models and mechanistic rationale, the authors found that clinical studies have not demonstrated substantial benefit from over-the-counter vitamin supplements on cancer patients' health or prognosis. The disconnect between preclinical promise and clinical reality is a recurring theme, and the review highlights the limitations of translating dietary interventions from controlled animal studies to the complex human cancer setting.
The authors also raise significant concern about the nutraceutical industry's promotion of unregulated supplements to vulnerable cancer patients. They argue that without a dedicated regulatory authority to verify product quality and clinical validity before commercialization, patients risk wasting resources on ineffective — or potentially harmful — products.
From a practical standpoint, the review suggests focusing on evidence-based dietary strategies to prevent cancer and support quality of life, rather than blanket supplementation. The call for regulatory oversight reflects a broader need for rigorous standards in the nutraceutical space, particularly for oncology populations who may be especially susceptible to misleading health claims.
Key Findings
- Clinical trials found no substantial benefit of over-the-counter vitamin supplements on cancer prognosis or patient health.
- Cancer patients frequently develop vitamin deficiencies due to inflammation, cachexia, and anticancer therapy side effects.
- Vitamins play key roles in antioxidant defense, immune response, epigenetics, and microbiota shaping relevant to cancer prevention.
- Dietary interventions like intermittent fasting and ketogenic diets showed mixed results with important limitations.
- Authors urge creation of a regulatory authority to ensure nutraceutical product quality before commercialization.
Methodology
This is a narrative review drawing on preclinical and clinical studies identified through PubMed and ClinicalTrials.gov. It covers mouse tumor models and human clinical trials examining vitamins, dietary supplements, and dietary interventions in cancer contexts. As a review, it synthesizes existing evidence rather than generating new primary data.
Study Limitations
The review is based only on the abstract, limiting assessment of the breadth and quality of included studies. As a narrative review, it may be subject to selection bias in the literature surveyed. The conclusions are broad and may not reflect nuance around specific vitamins, cancer types, or deficiency states.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.